On March 20, the 315 report named Baiya Corporation, stating that the company has no trading relationship with the involved violating company, nor does it have any association or cooperation relationship. Semiconductor equipment giant North Huachuang accelerates its acquisition pace of ChipSource, and a major deep-sea concept technology stock, ShenKai Co., Ltd., issued an announcement regarding unusual fluctuations, noting that the sales revenue of marine engineering products is relatively low...

Here are the selected after-market announcements:

Baiya Corporation: The company has not participated in the violating business mentioned in the 315 report

Baiya Corporation issued a response announcement to the Shenzhen Stock Exchange's inquiry letter, stating that after verification, the company is not aware of the violating business mentioned in the March 15 report and has not participated in such violating business. The company has no trading relationship with the involved violating company, nor does it have any association or cooperation relationship. Since the early morning of March 16, the company has taken over the entire process of handling defective products and has stopped cooperating with professional recycling entities regarding the disposal of waste materials. The company will destroy defective products using environmentally friendly incineration and other methods, completely eliminating the possibility of illegal recycling.

North Huachuang: Plans to bid for 8.41% of ChipSource shares

North Huachuang announced that the company plans to participate in the bidding for 8.41% of the shares of Shenyang ChipSource Microelectronics Equipment Co., Ltd., totaling 16,899,700 shares, with a listing price of no less than 85.71 yuan/share, totaling no less than 1.448 billion yuan. The company held a board meeting on March 20, 2025, and approved the relevant proposals, with the transaction funds sourced from its own funds. If this bidding is successful, combined with the previously planned acquisition of 9.49% of ChipSource shares, the company's shareholding in ChipSource will reach 17.9%. This bidding aims to promote the company's strategy and leverage the synergistic effects of both parties in the semiconductor equipment industry.

ShenKai Co., Ltd.: The low sales revenue of marine engineering products will not have a significant impact on the company's short-term performance

ShenKai Co., Ltd. issued an unusual announcement, stating that the company has noticed recent market attention on "deep-sea technology" related concepts. Some models of the company's wellhead, well control equipment, and logging instruments can be used for the exploration and development of offshore oil and gas resources. However, the sales revenue of related marine engineering products has accounted for only about 5% of the company's operating revenue over the past three years, which is relatively low and will not have a significant impact on the company's short-term performance.

HNA Holding: Subsidiary plans to renew lease for 2 B737-800 aircraft and lease 1 A321NEO aircraft

HNA Holding announced that its subsidiary, Xiangpeng Airlines, plans to renew the lease for 2 B737-800 aircraft from Yangtze River No. 79, with a total rent not exceeding 8 million USD; at the same time, it plans to lease 1 A321NEO aircraft from Yangtze River No. 3, with a total rent not exceeding 63 million USD. Both Yangtze River No. 79 and Yangtze River No. 3 are related parties of the company, and this transaction constitutes a related party transaction. The transaction has been approved by the board of directors and still needs to be submitted for shareholder meeting approval. This transaction is necessary for the company's normal production and operation, the transaction price is fair, and it will not adversely affect the company's ongoing operations and independence

Zhongguancun: Duoduo Pharmaceutical's Bromhexine Hydrochloride Injection Accepted by National Medical Products Administration

Zhongguancun announced that its subsidiary Duoduo Pharmaceutical's application for marketing authorization of Bromhexine Hydrochloride Injection (Specification: 2ml: 4mg) has been accepted by the National Medical Products Administration. This medication is used to treat chronic bronchitis and other respiratory diseases in cases where oral administration is difficult.

Tianhua New Energy: Subsidiary Yichun Shengyuan Obtains Mining License for Lithium-containing Ceramic Clay in Jiangxi Fengxin County

On March 20, Jinshi Futures reported that Tianhua New Energy announced that its subsidiary Yichun Shengyuan Lithium Industry Co., Ltd. has obtained a mining license for lithium-containing ceramic clay in the Jinzi Peak - Zuojiali mining area of Fengxin County, Jiangxi Province, issued by the Yichun Natural Resources Bureau. The mineral type is ceramic clay, the mining method is open-pit mining, with a production scale of 9 million tons/year, and the mining area is 0.8429 square kilometers, valid for 23 years (from March 7, 2025, to March 6, 2048). This matter will help the company increase its lithium mineral resource reserves, ensure resource supply, and enhance its core competitiveness. However, the company has not yet conducted comprehensive mining in the area, posing risks of discrepancies between forecasts and actual mining.

Yongxin Co., Ltd.: 2024 Net Profit of 468 Million Yuan, Up 14.63% Year-on-Year

Yongxin Co., Ltd. announced that its operating income for 2024 is 3.525 billion yuan, an increase of 4.34% year-on-year. The net profit attributable to shareholders of the listed company is 468 million yuan, an increase of 14.63% year-on-year. The basic earnings per share is 0.76 yuan/share, an increase of 13.43% year-on-year. The company plans to distribute a cash dividend of 6.2 yuan (including tax) for every 10 shares to all shareholders, with no bonus shares (including tax), and no capital reserve conversion to increase share capital.

Yingfeng Co., Ltd.: Plans to Repurchase Shares for 60 Million to 120 Million Yuan

Yingfeng Co., Ltd. announced that the company plans to repurchase shares with funds ranging from 60 million to 120 million yuan, with a repurchase price not exceeding 8 yuan/share. All repurchased shares will be used for implementing employee stock ownership plans or equity incentive plans, with an estimated repurchase quantity of 7.5 million to 15 million shares, accounting for 1.70% to 3.41% of the company's total share capital.

Kanghui Pharmaceutical: Actual Controllers to Change to Li Hongming and Wang Xuefang; Stock to Resume Trading Tomorrow

Kanghui Pharmaceutical announced that its controlling shareholder, Shaanxi Kanghui Holdings Co., Ltd., has signed a share transfer agreement with Jiaxing Yuehe Zhichuang Technology Partnership (Limited Partnership) on the same day. Kanghui Holdings intends to transfer 21.9736 million shares (accounting for 22% of the total shares of the company) to Yuehe Zhichuang at a transfer price of 24.7 yuan/share, totaling 543 million yuan. If the transaction is successfully completed, the company's controlling shareholder will change from Kanghui Holdings to Yuehe Zhichuang, and the actual controllers will change from Wang Yanling to the couple Li Hongming and Wang Xuefang. The company's stock will resume trading on March 21.

Guoguang Electric: Vice President Li Jing Resigns

Guangdong Electric Appliance announced that the company's board of directors received the resignation letter from Vice President Ms. Li Jing, who resigned from her position as Vice President and other roles due to personal reasons. After her resignation, Ms. Li Jing will not hold any position in the company and does not own any company shares.

Funeng Technology: Received Development Notification from XPeng Huitian

Funeng Technology announced that the company recently received a development notification from Guangdong Huitian Aerospace Technology Co., Ltd. XPeng Huitian has decided to select the company as the supplier of high-voltage power batteries, high-voltage connectors, and low-voltage connectors for its next-generation prototype. The receipt of this development notification is an important achievement from the company's years of layout in the low-altitude economy field, which will help the company consolidate its advantageous position in related fields and inject new momentum into the company's future growth.

Ningbo Dongli: Currently No Robot-Related Products and Performance

Ningbo Dongli, which has seen four consecutive trading limit-ups, announced that the company currently has no robot-related products and performance, which will not have a significant impact on the company's normal business activities, nor will it constitute a significant impact on the company's current performance and financial status, and there is no situation that harms the interests of the company and all shareholders.

Sankeshu: Received Government Subsidy Related to Revenue of 48.4385 Million Yuan

Sankeshu announced in the evening that its wholly-owned subsidiary, Anhui Sankeshu Coating Co., Ltd., received a government subsidy related to revenue of 48.4385 million yuan, accounting for 27.91% of the company's most recent audited net profit.

Yawen Shares: Currently No Controlling Shareholder and Actual Controller

Yawen Shares announced that the company's stock trading price has deviated by more than 20% in cumulative closing price increase over three consecutive trading days, which constitutes an abnormal fluctuation. After self-examination, the company confirms that there is no violation of information fair disclosure. The company's main business includes metal forming machine tools, laser processing equipment, and intelligent manufacturing solutions. The disclosure date for the company's 2024 annual report is April 28, 2025, and there is no situation requiring the disclosure of performance forecasts; undisclosed 2024 performance information has not been provided to any third party other than the accounting firm auditing the company. The company currently has no controlling shareholder and actual controller.

Dongzhu Ecology: No Controlling Relationship with Dilos and No Substantial Business Cooperation

Dongzhu Ecology announced an abnormal stock trading fluctuation, noting that the company has recently seen market reports regarding its subsidiary Dilos Artificial Intelligence Technology (Sichuan) Co., Ltd. (hereinafter referred to as "Dilos"). The company only holds a 10% stake in Dilos, does not have a controlling relationship with Dilos, and currently has no substantial business cooperation with it. Additionally, Dilos was established in January 2025 and is still in the startup phase, having not yet commenced operations, and its future operating performance remains uncertain. The company urges investors to pay attention to secondary market trading risks, make rational decisions, and invest cautiously.

China Mobile: Estimated Capital Expenditure of Approximately 151.2 Billion Yuan in 2025 Mainly for Computing Power Infrastructure Upgrades

China Mobile announced that according to its 2024 annual report, the company's total capital expenditure for 2024 is approximately RMB 164 billion. For 2025, the company expects total capital expenditure to be around RMB 151.2 billion, mainly used for optimizing connectivity infrastructure, upgrading computing power infrastructure, long-term infrastructure layout, and supporting CHBN technological innovation and perception enhancement. The required funds will mainly come from operating cash flow.

CRRC: President Jack Ma Shuang Resigns

CRRC announced that on March 20, 2025, the company's board of directors received the resignation letter from executive director and president Jack Ma Shuang. Mr. Jack Ma Shuang resigned from his positions as executive director, president, member of the board's Strategic and Sustainable Development Committee, and member of the Nomination Committee due to work adjustments. He also resigned from the position of authorized representative of the company under the Hong Kong Stock Exchange Listing Rules. After his resignation, Mr. Jack Ma Shuang will not hold any positions in the company or its holding subsidiaries.

China National Chemical: Contract Amount of RMB 53.42 Billion for January-February

China National Chemical announced that the company's contract amount for January-February 2025 was RMB 53.42 billion. Among them, the contract amount for construction engineering was RMB 51.47 billion, the contract amount for surveying, design, supervision, and consulting was RMB 326 million, the contract amount for industrial and new materials sales was RMB 1.518 billion, and the contract amount for modern service industry was RMB 106 million. The domestic contract amount was RMB 40.536 billion, and the overseas contract amount was RMB 12.884 billion.

Yiqiu Resources: Overseas Subsidiary Required to Repay Tax Subsidies

Yiqiu Resources announced in the evening that its overseas subsidiary YCTL received a notice from the Malaysian tax authority regarding the repayment of tax subsidies. The Malaysian tax authority requires YCTL to repay a total of 27.9434 million ringgit (approximately RMB 48.5 million) for the subsidies enjoyed in 2018 and 2020, along with corresponding late fees. There are still disputes between the company and the tax authority regarding the specific determination of this matter, and both parties are currently actively communicating and negotiating. The final repayment amount and deadline will be subject to the tax authority's final ruling. This matter will not have a significant adverse impact on the company's business operations.

Minsheng Health: Plans to Repurchase 0.36%-0.41% of Total Shares

Minsheng Health announced that the company plans to repurchase its issued unrestricted ordinary shares (A shares) for equity incentives. The repurchase price will not exceed RMB 19.80 per share, and the estimated number of shares to be repurchased is between 1.3 million and 1.45 million shares, accounting for 0.36%-0.41% of the company's current total share capital. The total amount of funds for the repurchase is expected to not exceed RMB 28.71 million. The repurchase period is within 12 months from the date the board of directors approves the repurchase plan.

Hengtong Optic-Electric: Recently Won 1.133 Billion Yuan Marine Energy Project

Hengtong Optic-Electric announced that the company and its holding subsidiaries recently received project "Bid Notification" or signed project contracts, confirming the winning of domestic and foreign marine energy projects, with a total bid amount of RMB 1.133 billion. The winning projects include the procurement of submarine cables, procurement and construction laying of cables and accessories, ship leasing, marine pipes, and static flexible pipes, etc The performance of the project contract is expected to have a positive impact on the company's future operating performance, with the bid amount accounting for 2.38% of the company's audited operating income for 2023.

2 Lianban Far East Transmission: The company does not violate information fair disclosure

Far East Transmission announced an abnormal stock trading fluctuation, stating that the company's current production and operation situation is normal, and there have been no significant changes in the internal and external operating environment. After self-examination, the company does not violate information fair disclosure. The pre-disclosure date for the company's 2024 annual report is April 9, 2025, and there is no need to disclose performance forecasts; there is no undisclosed 2024 performance information provided to any third party other than the accounting firm auditing the company.

Junshi Biosciences: Clinical trial application for injectable JS212 approved

Junshi Biosciences announced that the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, and the clinical trial application for injectable JS212 has been approved.

Kang En Bei: Subsidiary's acetylcysteine solution approved by the US FDA

Kang En Bei announced that its wholly-owned subsidiary, Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., has received notification from the US Food and Drug Administration (FDA) that the abbreviated new drug application (ANDA) for acetylcysteine solution submitted to the FDA has been approved.

Kew Flower Pharmaceutical: Appointed Yang Yang and Liu Guangtao as deputy general managers

Kew Flower Pharmaceutical announced on March 20 that, based on the nomination by the company's general manager (president), the fifth board of directors' nomination committee and the compensation and assessment committee reviewed and approved, the company's board of directors decided to appoint Yang Yang and Liu Guangtao as deputy general managers, with their term starting from the date of board approval until the end of the current board's term.

Guangdong Hongda: Head of internal audit department Hu Yanyan resigns due to work adjustment

Guangdong Hongda announced that the company's board of directors recently received a written resignation report from Hu Yanyan, head of the internal audit department, who applied to resign from the position due to work adjustment. After resigning, Hu Yanyan will continue to hold other positions in the company's subsidiaries. According to relevant regulations, Hu Yanyan's resignation report takes effect from the date it is delivered to the board of directors, and her resignation will not have a significant impact on the company's daily operations. The company will complete the appointment of the head of the internal audit department as soon as possible.

Yonghui Superstores: Board authorizes reform leadership team to act as CEO

Yonghui Superstores announced that, since the sixth board of directors has not yet appointed a CEO, the board has authorized the company's reform leadership team to act as CEO to ensure the company's standardized operation and smooth conduct of daily management matters. The company will complete the selection of a CEO as soon as possible.

Pinggao Co., Ltd.: Guangzhou Xusheng terminates the reduction plan early

Pinggao Co., Ltd. announced in the evening that its shareholder Guangzhou Xusheng Enterprise Management Consulting Partnership (Limited Partnership), which holds 3.78% of the shares, originally planned to reduce its holdings of no more than 1.89% of the company's shares through block trading. As of March 20, 2025, Guangzhou Xusheng has cumulatively reduced its holdings of 1% of the company's shares through block trading Considering the current market environment and its own operational funding arrangements, and based on confidence in the company's future development prospects and recognition of the company's value, Guangzhou Xusheng has decided to terminate this reduction plan in advance.

Weigao Medical: Did Not Participate in Media Reported Illegal Activities

Weigao Medical announced that the company recently received a letter of concern from the Shenzhen Stock Exchange, requesting a self-examination regarding the matters related to All Cotton Era sanitary products mentioned in media reports. The company quickly formed a special team to conduct a comprehensive self-examination and cooperated with market supervision and management departments in the investigation, and has reported to the public security authorities. The self-examination results show that the company did not participate in the illegal activities mentioned in the reports and has no trading or cooperative relationship with the companies involved. In addition, the company implements strict internal control systems in raw material procurement and defective product disposal, and no cases of unqualified raw materials or defective products circulating have been found. The company promises to take measures to improve management systems and strengthen the control of defective products to protect consumer interests